[English]  [Pусский]  [中文]  
ctt-journal > Arshanskaya et al. (Abstract)

Arshanskaya et al. (Abstract)

Cellular Therapy and Transplantation (CTT), Vol. 3, No. 9
doi: 10.3205/ctt-2010-No9-abstract49
© The Authors. This abstract is provided under the following license: Creative Commons Attribution 3.0 Unported

Abstract accepted for "4th Raisa Gorbacheva Memorial Meeting on Hematopoietic Stem Cell Transplantation",
Saint Petersburg, Russia, September 18–20, 2010

Contribute a comment


Quality of life in patients in prolonged remission from Hodgkin's lymphoma (HL)

Evgeniya G. Arshanskaya, Sergey V. Semochkin, Vadim V. Ptushkin, Alexander G. Rumiantsev

Federal Scientific Clinical Center of Pediatric Hematology, Oncology and Immunology, Moscow, Russia

Correspondence: Evgeniya G. Arshanskaya, Federal Scientific Clinical Center of Pediatric Hematology, Oncology and Immunology, 117/2, Leninsky pr., 117997, Moscow, Russia, E-mail: arsevgeniya@spam is badyandex.ru


HL is a potentially curable disease for most patients. The modern concept of treatment of children and adolescents with HL, implemented in the German-Austrian protocol DAL-HD-90, aims at minimizing the doses and fields of radiation therapy (RT) and reducing the total doses of alkylating agents and anthracyclines in order to decrease the risk of late events (secondary tumors, endocrine and cardiovascular complications), violations of fertility, and preservation of QoL of cured patients. The assessment of QoL is an important method of studying the patient’s status, as it integrates physical, psychological, and social well-being characteristics.

The purpose of this work was the investigation of QoL in cured patients in long-term remission after therapy (in accordance with protocol DAL-HD-90m) in comparison with a healthy control group.

Patients and methods: During the period 1995–2007, 94 patients (m: – 37, f: – 57) aged 15 to 29 (median 16.7 years) were enrolled after treatment with a radiotherapy-modified DAL-HD-90 protocol. Health-related QoL research was confined to the patients without signs of progression or relapse, and with a complete response duration  lasting longer than five years at the time of the questionnaire. The controls were healthy students with no medical profile (n=50; median age 23.4; range 18–32 years). The questionnaire used was EORTC QLQ-C30.

Results: Complete response was reached in 91% of patients. Six-year overall survival was 0.93±0.03; and event free survival, – 0.84±0.06. In the cancer survivor group there was a high frequency of nausea and vomiting and dyspnoea (Fig. 1) in comparison with the healthy volunteers. On the other hand, fatigue was higher in the healthy volunteers, which was most likely caused by a higher level of social and physical activity. The global health status was similar in both groups.

Figure 1. Comparative analysis of QoL of patients with prolonged remission in Hodgkin's lymphoma and healthy volunteers.
* - p < 0,05

Conclusions: The revised DAL-HD-90 protocol provides a high QoL in adolescents and young adults cured of Hodgkin’s lymphoma comparable to that in their healthy contemporaries.
Keywords: Hodgkin’s lymphoma, prolonged remission, quality of life, adolescents


<-- Previous abstract        Contents        Next abstract -->

Contribute a comment